Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Technical Presentation (August 2024)

16 slides from Neurocrine Biosciences's technical presentation, Aug 28, 2024

  1. Slide 1: Topline Results for Phase 2 Trial of NBI-1117568 (NBI-'568) in Schizophrenia

    Topline Results for Phase 2 Trial of NBI-1117568 (NBI-’568) in Schizophrenia August 28, 2024

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the clinical results from, and our future development plans with

  3. Slide 3: Agenda

    Agenda 1 Introduction Kevin Gorman, Ph.D. | Chief Executive Officer Trial Design & Results 2 Eiry Roberts, M.D. | Chief Medical Officer 3 Q&A Kevin Gorman, Ph.D. | Chief Executive Officer Kyle Gano, Ph.D. | Chief Business Development and Strategy Officer Jude Onyia, Ph.D. | Chief Scientific Officer

  4. Slide 4: Summary of Phase 2 Topline Results

    Summary of Phase 2 Topline Results Once-Daily 20mg Dose: Efficacy, Safety, and Tolerability Results Support Advancement to Phase 3 20mg Once-daily Demonstrated Efficacy, Safety and Tolerability Profile Statistically Significant and Clinically Generally Safe and Well-tolerated Combined With Once-dail

  5. Slide 5: Trial Design & Results

    Trial Design & Results 5

  6. Slide 6: NBI-'568 Phase 2 Study Design

    NBI-’568 Phase 2 Study Design Dose-finding Study Using a First-in-Class Selective M4 Agonist Placebo Placebo Placebo INTERIM INTERIM ANALYSIS ANALYSIS 20 mg QD 1 20 mg QD 2 20 mg QD Titrate Titrate Titrate 20 mg 40 mg QD 20 mg 40 mg QD 20 mg 40 mg QD Titrate Titrate Randomization 1:1:1 60mg QD to Pl

  7. Slide 7: Baseline Characteristics and Demographics Summary

    Baseline Characteristics and Demographics Summary Placebo 20mg QD 40mg QD 60mg QD 30mg BID All Subjects \ N=70 N=40 N=39 N=34 N=27 N=210 Disease Characteristics At Baseline PANSS Total Score, mean 97 97 95 96 98 96 Demographics Age (years), mean 40 41 41 40 41 41 Male: n​ (%) 60 (85.7)​ 31 (77.5)​ 3

  8. Slide 8: Once-Daily 20mg Dose Met Primary Endpoint

    Once-Daily 20mg Dose Met Primary Endpoint PANSS Total Score vs Placebo Placebo 20mg QD 40mg QD 60mg QD 30mg BID Week 6 N=68 N=35 N=38 N=34 N=26 PANSS Total Score LS Mean Change from Baseline* -10.8 -18.2 -12.6 -13.7 -15.8 -7.5 -1.9 -2.9 -5.0​ LS Mean Difference vs. Placebo, p-value* p = 0.011​​ p =

  9. Slide 9: Once-Daily 20mg Dose Demonstrated Clinically Meaningful and Statistically Significant Efficacy at Week 3, 4, 5, and 6

    Once-Daily 20mg Dose Demonstrated Clinically Meaningful and Statistically Significant Efficacy at Week 3, 4, 5, and 6 0 20mg QD Efficacy Data PANSS Total Score Change from Baseline LS Mean1 ± SEM -5.7 Week 4 – Week 6 -5 -8.2 -7.7 Week 4 5 6** -9.6 PANSS Total Score -8.4 -10.2 -10 -10.8 -11.5 LS Mean

  10. Slide 10: Once-Daily 20mg Dose Demonstrated Statistically Significant Improvement in Additional Endpoints

    Once-Daily 20mg Dose Demonstrated Statistically Significant Improvement in Additional Endpoints \ CGI-S Marder Factor — Positive Marder Factor — Negative Placebo 20mg QD Placebo 20mg QD Placebo 20mg QD Week 6 N=68 N=35 N=68 N=35 N=68 N=35 LS Mean Change from Baseline* -0.5 -1.2 -2.8 -5.8 -1.2 -3.1 L

  11. Slide 11: NBI-'568 Was Generally Safe and Well Tolerated at All Doses Studied

    NBI-’568 Was Generally Safe and Well Tolerated at All Doses Studied Treatment-Emergent Adverse Events Occurring in ≥ 5% of NBI-'568 All Treated Group Placebo 20mg QD 40mg QD 60mg QD 30mg BID All Treated \ N=70 N=40 N=39 N=34 N=27 N=140 Somnolence 2 (2.9) 5 (12.5) 2 (5.1) 7 (20.6) 1 (3.7) 15 (10.7) D

  12. Slide 12: NBI-'568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist in Clinical Development

    NBI-’568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist in Clinical Development Type of Large Opportunity For NBI-'568, A Novel And Subtype Requires Endogenous Muscarinic Differentiated Asset Selectivity Ligand (Acetylcholine) Activation With no reliance on innate acetylcholine le

  13. Slide 13: NBI-'568 Effect Size Comparable to Known Muscarinic Programs and Leading Antipsychotics

    NBI-’568 Effect Size Comparable to Known Muscarinic Programs and Leading Antipsychotics Clinical-Stage Muscarinic Programs Leading Approved Treatments 0.75 0.68 0.61 0.61 0.60 Effect Size 0.56 0.55 0.42 0.41 0.36 0.34 0.3 0.26 125mg / 30mg 30mg QD 125mg / 30mg 20mg 125mg / 30mg Zyprexa Risperdal Ser

  14. Slide 14: Validation of Selective Orthosteric Agonist Mechanism Strengthens Conviction In Muscarinic Portfolio

    Validation of Selective Orthosteric Agonist Mechanism Strengthens Conviction In Opportunities For Industry Leading Muscarinic Portfolio Primary Mechanism Phase Therapeutic Areas Potential Areas For Development (M1-M4) NBI-1117568 NBI-1117568 M4 agonist 2 Alzheimer’s Disease NBI-1117567 M1 agonist 1

  15. Slide 15: Summary of Topline Results

    Summary of Topline Results NBI-'568 20mg once-daily dose demonstrated meaningful improvement in PANSS Total Score at Week 6: • 18.2 point improvement in PANSS Total Score NBI-'568 Has A Differentiated Profile Vs. • 7.5 point placebo-adjusted improvement Other Antipsychotics: • Effect size of 0.61 No

  16. Slide 16: Q&A

    Q&A Kevin Gorman, Kyle Gano, Jude Onyia, Eiry Roberts, Samir Jaz Singh, Ph.D. Ph.D. Ph.D. M.D. Siddhanti M.D. Chief Executive Chief Business Chief Scientific Officer Chief Medical Officer VP Business VP Clinical Officer Development and Development & Development, Strategy Officer Muscarinic Agonist P

Neurocrine Biosciences — Technical Presentation (August 2024) on 6ix